LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

Epigenetic regulators are recurrently mutated and aberrantly expressed in acute myeloid leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes, such as the histone demethylase lysine-specific demethylase 1 (LSD1) and the histone methyltransferase DOT1L, have been de...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Cusan, Monica, Cai, Sheng F., Mohammad, Helai P., Krivtsov, Andrei, Chramiec, Alan, Loizou, Evangelia, Witkin, Matthew D., Smitheman, Kimberly N., Tenen, Daniel G., Ye, Min, Will, Britta, Steidl, Ulrich, Kruger, Ryan G., Levine, Ross L., Rienhoff, Hugh Y., Koche, Richard P., Armstrong, Scott A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Myeloid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5897868/
https://ncbi.nlm.nih.gov/pubmed/29453291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-807024
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky